Victory Capital Management Inc. Raises Stock Position in Avantor, Inc. (NYSE:AVTR)

Victory Capital Management Inc. lifted its stake in Avantor, Inc. (NYSE:AVTR) by 15.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 322,469 shares of the company’s stock after purchasing an additional 42,132 shares during the period. Victory Capital Management Inc.’s holdings in Avantor were worth $8,342,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Versant Capital Management Inc boosted its holdings in shares of Avantor by 2,003.6% during the 2nd quarter. Versant Capital Management Inc now owns 1,157 shares of the company’s stock valued at $25,000 after buying an additional 1,102 shares in the last quarter. Blue Trust Inc. increased its stake in shares of Avantor by 1,830.3% during the second quarter. Blue Trust Inc. now owns 1,467 shares of the company’s stock valued at $31,000 after purchasing an additional 1,391 shares in the last quarter. UMB Bank n.a. purchased a new position in shares of Avantor during the third quarter valued at approximately $49,000. Nisa Investment Advisors LLC grew its stake in shares of Avantor by 69.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock worth $53,000 after buying an additional 835 shares during the last quarter. Finally, GAMMA Investing LLC increased its position in Avantor by 89.9% during the 3rd quarter. GAMMA Investing LLC now owns 2,715 shares of the company’s stock valued at $70,000 after buying an additional 1,285 shares in the last quarter. Institutional investors own 95.08% of the company’s stock.

Wall Street Analysts Forecast Growth

AVTR has been the subject of a number of research analyst reports. Stifel Nicolaus lifted their price target on shares of Avantor from $27.00 to $28.00 and gave the stock a “buy” rating in a research note on Monday, July 29th. Royal Bank of Canada reiterated an “outperform” rating and issued a $34.00 price objective on shares of Avantor in a research note on Thursday, September 26th. Robert W. Baird cut their target price on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research report on Monday, October 28th. Morgan Stanley increased their price target on shares of Avantor from $28.00 to $29.00 and gave the stock an “overweight” rating in a research report on Monday, July 29th. Finally, Wells Fargo & Company lowered their price objective on Avantor from $30.00 to $28.00 and set an “overweight” rating on the stock in a research report on Monday, October 28th. Three research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $27.57.

Insider Buying and Selling at Avantor

In other news, CAO Steven W. Eck sold 3,525 shares of the business’s stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $25.06, for a total transaction of $88,336.50. Following the completion of the sale, the chief accounting officer now directly owns 29,544 shares of the company’s stock, valued at approximately $740,372.64. The trade was a 10.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 1.50% of the company’s stock.

Avantor Price Performance

Avantor stock opened at $20.36 on Friday. The company has a market cap of $13.86 billion, a price-to-earnings ratio of 44.26, a PEG ratio of 2.39 and a beta of 1.35. Avantor, Inc. has a 52-week low of $19.59 and a 52-week high of $28.00. The company has a quick ratio of 1.06, a current ratio of 1.54 and a debt-to-equity ratio of 0.84. The firm’s fifty day moving average is $24.01 and its 200 day moving average is $23.89.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.